Dr Mark Stanchfield, OD in Cut Bank, MT - Medicare Optometry Provider

Dr Mark Stanchfield, OD is a medicare enrolled "Optometrist" provider in Cut Bank, Montana. He went to Southern California College Of Optometry and graduated in 1986 and has 38 years of diverse experience with area of expertise as Optometry. His current practice location is 226 9th Ave Se, Cut Bank, Montana. You can reach out to his office (for appointments etc.) via phone at (406) 873-5623.

Dr Mark Stanchfield is licensed to practice in Montana (license number 516) and he also participates in the medicare program. He may accept medicare assignments (which means he may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance) and his NPI Number is 1235118258.

Contact Information

	Dr Mark Stanchfield, OD
	226 9th Ave Se, Cut Bank, MT 59427-3332
	(406) 873-5623
	(406) 873-5624

Healthcare Provider's Profile

Full Name	Dr Mark Stanchfield
Gender	Male
Speciality	Optometry
Experience	38 Years
Location	226 9th Ave Se, Cut Bank, Montana
Accepts Medicare Assignments	May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Mark Stanchfield attended and graduated from Southern California College Of Optometry in 1986

NPI Data:

NPI Number: 1235118258
Provider Enumeration Date: 01/10/2006
Last Update Date: 04/30/2009

Medicare PECOS Information:

PECOS PAC ID: 8123198447
Enrollment ID: I20080529000461

Medical Identifiers

Medical identifiers for Dr Mark Stanchfield such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1235118258	NPI	-	NPPES
048-1377	Medicaid	MT
1235118258	Other	MT	NPI
0249250001	Other	MT	MEDICARE NSC

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
152W00000X	Optometrist	516 (Montana)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Mark Stanchfield is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Mark Stanchfield, OD 226 9th Ave Se, Cut Bank, MT 59427-3332 Ph: (406) 873-5623	Dr Mark Stanchfield, OD 226 9th Ave Se, Cut Bank, MT 59427-3332 Ph: (406) 873-5623

News Archive

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

Deloitte Consulting offers new sales strategy for pharmaceutical companies

Pharmaceutical companies face a fundamental decision about the best way to sell their products. Even if they could find a way to make the current sales model work, pharma companies still face sky-high commercial costs. So, the question is, should pharma companies stick with their traditional sales approach or blow it up and try something new?

DiaTech Oncology files patent for Drug Discovery to validate cancer treatment

DiaTech Oncology has announced the filing of a patent for Drug Discovery that will provide a new strategy and approach to validate drugs that may be more effective in treating cancer patients

Halozyme awarded $977,917 grant under Qualifying Therapeutic Discovery Project program

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.

Leopoldina Annual Assembly to focus on factors that shape individual personalities

The German National Academy of Sciences Leopoldina will focus on the theme "Geist - Gehirn - Genom - Gesellschaft ("Mind, brain, genome and society") at its 2013 Annual Assembly, which will take place from 20 to 22 September and welcome over 400 guests from around the world to Halle (Saale).

Dr Mark Stanchfield, OD - Medicare Optometrist in Cut Bank, MT